Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

 
• By Anju Ghangurde

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.

Lung conference
Dr Mel Spigelman, President and CEO, TB Alliance • Source: TB Alliance

More from Business

More from Scrip